Sangamo Therapeutics (SGMOQ) Depreciation & Amortization (CF) (2010 - 2025)

Sangamo Therapeutics has reported Depreciation & Amortization (CF) for 16 years, with the latest figure at $998000.0 in Q4 2025.

• On a quarterly basis, Depreciation & Amortization (CF) fell 19.58% year-over-year to $998000.0 in Q4 2025; TTM through Dec 2025 was $4.0 million, a 21.68% decrease from a year earlier, with the FY2025 full-year figure at $4.0 million, down 21.68% from the prior year.
• Depreciation & Amortization (CF) was $998000.0 for Q4 2025 at Sangamo Therapeutics, up from $989000.0 in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $5.5 million in Q3 2023, with the low at $989000.0 in Q3 2025.
• Average Depreciation & Amortization (CF) over 5 years is $2.3 million, with a median of $2.1 million recorded in 2021.
• The sharpest annual moves came in 2021 and 2024: Depreciation & Amortization (CF) surged 87.87% in 2021, then plunged 77.83% in 2024.
• Over 5 years, Depreciation & Amortization (CF) stood at $2.8 million in 2021, then grew by 20.95% to $3.3 million in 2022, then sank by 44.3% to $1.9 million in 2023, then plunged by 33.35% to $1.2 million in 2024, then decreased by 19.58% to $998000.0 in 2025.
• The last three Depreciation & Amortization (CF) figures came in at $998000.0 (Q4 2025), $989000.0 (Q3 2025), and $993000.0 (Q2 2025), per Business Quant data.